Healthcare EPINEPHRINE AUTO INJECTOR MARKET IS PROJECTED TO GROW UP TO 13.5% CAGR DURING THE FORECAST...


EPINEPHRINE AUTO INJECTOR MARKET IS PROJECTED TO GROW UP TO 13.5% CAGR DURING THE FORECASTING PERIOD 2021-2027.

An epinephrine autoinjector is a medical device that injects epinephrine or adrenaline into the body to treat anaphylaxis. These are small, portable devices that contain a fixed dose of epinephrine and a spring-loaded needle that delivers the medication to people who have serious allergic reactions or anaphylaxis. The cost effectiveness and usability issues have always been a topic of discussion. Epinephrine injectors, also known as EpiPen, are instruments that administer the drug epinephrine. When anyone is discovered to be suffering from severe allergic reactions, also known as anaphylaxis, it is considered one of the life-saving medications. This medicine aids in the prevention of allergic reactions in the body as a whole. It aids in the narrowing of blood vessels associated with high blood pressure and decreases swelling. This helps the body to relax by opening the lungs to allow air to enter.

Request for a sample report: https://whipsmartmi.com/sample/he0502/Epinephrine-Auto-Injector-Market

Key Driving Factors: Anaphylaxis in adults is becoming more common:

The primary factor driving the growth of the high dose segment is the increasing occurrence of anaphylaxis in adults, especially among the elderly. Since epinephrine is the first-line treatment for anaphylaxis, the segment's growth is being fueled by the increasing recommendation of high dose by healthcare professionals (HCP) around the world for adult patients. Furthermore, industry players are concentrating on offering generic, low-cost drugs, which is pushing up demand for reliable anaphylactic reaction treatment options. Several social and emotional factors, such as risk-taking habits with food and disease denial, lead to the high incidence of anaphylaxis in adolescent and adult populations. The market forces are guided by all of these factors.

This report offers the major market player’s profiles, such as Teva Pharmaceutical Industries Ltd., Antares Pharma, ALK-Abell A/S, Adamis Pharmaceuticals Corporation, Lincoln Medical Centre Ltd., Mylan N.V., Impax Laboratories, Inc., Pfizer Inc., Bausch & Lomb Incorporated, and Kaleo, Inc. 

Opportunities: Regulatory bodies' urging act of safeguarding:

Anaphylaxis is becoming more common in children, necessitating prompt and appropriate treatment. Government and regulatory authorities are working to develop safeguarding policies in order to avoid fatal reactions in children aged 6 to 12. Epinephrine auto-injectors work quickly to relieve the most severe symptoms in infants, such as throat swelling, breathing difficulties, and low blood pressure. As a result, it is still advised to have epinephrine auto-injectors on hand for children in schools to prevent catastrophic anaphylaxis reactions, which will broaden the market in the immediate future.

By Dosage:

The global epinephrine auto-injector market can be divided into three categories based on dosage: 0.15 mg, 0.30 mg, and 0.50 mg. During the forecast period, the 0.30 mg segment of the global epinephrine auto-injector market is expected to grow at a rapid rate. During the forecast era, the segment is projected to be powered by an increase in the volume sales of generic epinephrine auto-injectors.

The Epinephrine Auto Injector market report has been categorized as below


By Dosage

  • 0.15mg Epinephrine Autoinjector
  • 0.3mg Epinephrine Autoinjector
  • 0.5mg Epinephrine Autoinjector


By End Users

  • Hospitals
  • Clinics
  • Home Based
  • Others

By Age Group

  • 0-4 Years
  • 5-14 Years
  • 15-24 Years
  • 25-49 Years
  • 50-64 Years
  • Above 65 Year

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of World

Access to Full Report Summary: https://whipsmartmi.com/Report/Epinephrine-Auto-Injector-Market

Published Date : March-2021